XBiotech Inc.

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies to treat various diseases. The company was incorporated in Canada on March 22, 2005. XBiotech's True Human™ monoclonal antibodies are sourced from human donors who exhibit a natural human immune response, differentiating them from other marketed antibody therapeutics derived from animal immunization. The company has developed a pipeline of product candidates aimed at both inflammatory and infectious diseases. XBiotech has also created manufacturing technology designed to reduce the cost and time involved in launching new product candidates. The company operates a state-of-the-art research and manufacturing center located on its 48-acre research campus in Austin, Texas, making it a fully integrated developer of biopharmaceuticals. A key medical focus for XBiotech is developing therapies that block interleukin-1 alpha (IL-1a), a substance involved in several pathophysiological processes, including tissue breakdown (such as synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, blood clot formation, malaise, muscle wasting, and general inflammation.